^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Ovarian Cancer |
| Regimen: | CPB (Avastin (bevacizumab) + carboplatin + paclitaxel) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: Exploratory analyses
Published date:
03/19/2021
Excerpt:
PFS prognosis (assessed in the placebo + CPB arm) was improved in patients with BRCA1/2m (hazard ratio [HR] 0.62, 95% CI 0.46–0.84) and HRD (HR 0.63, 95% CI 0.49–0.80) tumors. There was a suggested association between PD-L1+ and HRD (HRD prevalence: 40% vs 25% in PD-L1+ vs PD-L1– subgroups...
Trial ID:
Test:
